预约演示
更新于：2026-02-08
Lidocaine Hydrochloride
盐酸利多卡因
更新于：2026-02-08
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1948-11-19), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C14H25ClN2O2 |
InChIKeyYECIFGHRMFEPJK-UHFFFAOYSA-N |
CAS号6108-05-0 |
关联
263
项与 盐酸利多卡因 相关的临床试验NCT07224711
The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Abdominal Surgery (IMPALA ERAS)
NCT07054801
Intra-arterial Lidocaine and Methylprednisolone Injection Into the Middle Meningeal Artery For Treatment of Headache Associated With Subarachnoid Hemorrhage
NCT07333859
Effect of Intravenous Lidocaine Infusion on Duodenal Peristalsis, Sedation Quality and Rescue Spasmolytic Requirement in ERCP Procedures: A Randomized, Double-Blind, Placebo-Controlled Study
100 项与 盐酸利多卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸利多卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸利多卡因 相关的专利（医药）
登录后查看更多信息
12,149
项与 盐酸利多卡因 相关的文献（医药）2026-04-01DEN open
Comparison effectiveness of topical analgesics with and without Entonox for esophagogastroduodenoscopy: A randomized controlled trial
Article
作者: Noitasaeng, Papiroon ; Chaiwong, Rojsirin ; Kaosombatwattana, Uayporn ; Vichitvejpaisal, Phongthara
Abstract:
Objectives:
Esophagogastroduodenoscopy (EGD) is vital for diagnosing and treating upper gastrointestinal symptoms, but patient discomfort and anxiety can affect procedural outcomes. This study aimed to compare the effectiveness of topical analgesics with and without Entonox during EGD in terms of procedural success, patient tolerance, and satisfaction.
Methods:
A prospective, randomized, double‐blinded, controlled trial. Patients were assigned to receive either 10% xylocaine spray in the control group (Group C) or 10% xylocaine spray combined with Entonox (Group E). Procedural success and patient comfort were evaluated using the Bath Gastroscopy Toleration Score and patient comfort scores, with scores of 0 or 1 indicating success. Satisfaction was measured using the numeric rating scale, where scores of 7 or higher indicated high satisfaction.
Results:
A total of 211 patients underwent EGD successfully (Group C = 106, Group E = 105). Patients in Group E demonstrated a significantly higher proportion of success rate (76.2% vs. 35.9%, p < 0.001), better toleration score (82.9% vs. 75.5%, p = 0.004), and better patient comfort score (86.7% vs. 39.6%, p < 0.001) compared to Group C. Endoscopists and patients in Group E expressed higher satisfaction levels (9 vs. 8, p < 0.01 and 9 vs. 8, p < 0.01). The side effects of Entonox were minimal. Notably, Group E had a lower proportion of high blood pressure and tachycardia during the procedure (p < 0.001).
Conclusions:
Combining Entonox with topical analgesics significantly improves tolerance, satisfaction, and procedural success during EGD, offering a safe and effective option for managing patient discomfort and anxiety.
2026-03-01Brain Stimulation
Trigeminal nerve direct current stimulation modulates raphe–hippocampal network synchrony in rats
Article
作者: Majdi, Alireza ; Mc Laughlin, Myles ; Chen, Liyi
BACKGROUND:
Trigeminal nerve stimulation is a promising noninvasive method to modulate subcortical circuits involved in cognition. This study investigated the influence of trigeminal nerve direct current stimulation (TN-DCS) on neuronal activity and coherence between the raphe nuclei and hippocampus.
METHODS:
Fourteen adult male Sprague-Dawley rats (n = 10 control; n = 4 xylocaine/agonist) were implanted with silicon probes for simultaneous recordings from the hippocampus and either the dorsal (DRN) or median raphe nucleus (MnRN). Direct currents (from ±0.25 to ±3 mA) were applied to the trigeminal nerve during 3-min sessions (1 min pre-, 1 min during, 1 min post-stimulation).
RESULTS:
Acute TN-DCS rapidly and reversibly modulated firing in the DRN, MnRN, and hippocampus in a cell-type-specific, amplitude-dependent manner. Putative non-serotonergic (p-non-SERT) raphe neurons exhibited strong increases in spike rate, whereas putative serotonergic (p-SERT) neurons did not show consistent rate changes or stimulation-induced bursts. In the hippocampus, pyramidal cells exhibited polarity-dependent, amplitude-scaled increases in spike rate, whereas interneurons displayed smaller effects that were independent of polarity. TN-DCS enhanced theta-band coupling between p-non-SERT raphe spikes and hippocampal local field potentials, increasing spike-field coherence and spike-triggered averages in both DRN and MnRN. These effects, along with spike-rate increases in MnRN and hippocampus caused by TN-DCS, were blocked or significantly reduced by local trigeminal block (xylocaine) or intra-MnRN 5-HT1A/7 agonist (8-OH-DPAT).
CONCLUSIONS:
TN-DCS dynamically modulates raphe-hippocampal firing and theta synchrony via predominantly amplitude-dependent mechanisms that require intact trigeminal input and serotonergic signaling, supporting its potential as a targeted neuromodulation approach for subcortical circuits involved in cognition and mood.
2026-01-26Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
In Vitro Effects of Liquid Cardiac Drugs on Human Catalase Enzyme.
Article
作者: Argan, Onur ; Çıkrıkcı, Kübra ; Gençer, Nahit
OBJECTIVE:
When liquid medications are administered intravenously, the first cellular defense encountered by the drug is erythrocytes. Catalase is the main antioxidant system in erythrocytes. Drug-related catalase inhibition can cause adverse effects. Although catalase is a well-known enzyme, studies investigating drug-catalase interactions are scarce in the literature. Therefore, we investigated the impact of liquid cardiac drugs on human erythrocyte catalase activity in vitro.
METHOD:
Catalase activity was determined by a spectrophotometric method using a procedure developed by Aebi. Liquid cardiac drugs were incubated with human blood in vitro. IC50 values were compared among the drugs.
RESULTS:
The most potent inhibitors were noradrenaline (IC50: 4.61 µM), adrenaline (IC50: 32.58 µM), and amiodarone hydrochloride (IC50: 41.86). Dopamine hydrochloride (IC50: 429.15 µM) and lidocaine hydrochloride (IC50: 453.1 µM) showed less inhibitory effects on catalase activity compared with adenosine (IC50: 58.49 µM), atropine sulfate (IC50: 68.75 µM), dobutamine hydrochloride (IC50: 80.79 µM), glyceryl trinitrate (IC50: 86.66 µM), and heparin sodium (IC50: 92.4 µM).
CONCLUSION:
Noradrenaline, adrenaline, and amiodarone hydrochloride have strong inhibitory effects on catalase activity. Catalase inhibition may be responsible for the side effects of these drugs. Therefore, when these drugs are used in treatment, their dosages and duration of administration should be carefully controlled to prevent adverse effects due to catalase enzyme inhibition.
100 项与 盐酸利多卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2007-08-16 | |
| 室性心律失常 | 美国 | 1980-12-19 | |
| 室性心动过速 | 中国 | 1976-01-01 | |
| 麻醉 | 美国 | 1948-11-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性疼痛 | 临床3期 | 中国 | 2018-08-15 | |
| 导管部位不适 | 临床3期 | 中国 | 2018-08-15 | |
| 宫颈癌 | 临床3期 | 中国 | 2018-08-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 26 | (Placebo + FOLFOX) | 獵積顧選鏇憲衊製糧壓(繭簾獵積範獵衊憲齋艱) = 簾鏇顧構艱憲製築願選 積衊鹹廠齋鹹遞遞網繭 (糧鑰鑰蓋鏇糧鬱廠鏇壓, 18.3) 更多 | - | 2022-03-09 | ||
(Lidocaine + FOLFOX) | 獵積顧選鏇憲衊製糧壓(繭簾獵積範獵衊憲齋艱) = 艱夢繭觸糧鏇淵鑰淵廠 積衊鹹廠齋鹹遞遞網繭 (糧鑰鑰蓋鏇糧鬱廠鏇壓, 14.4) 更多 | ||||||
临床4期 | - | 23 | 觸鬱襯醖壓網夢窪壓壓(觸築餘觸夢簾築選衊製) = 顧艱範憲製窪網壓蓋衊 襯齋繭選觸齋觸膚鹹製 (繭齋製壓繭簾鬱鹹鬱醖, 製網觸顧鹹鬱壓獵膚衊 ~ 獵獵構壓觸餘觸鑰構網) 更多 | - | 2021-11-01 | ||
临床2期 | - | 200 | 積壓觸簾顧憲蓋蓋鑰構(觸鹹壓壓積鹹廠餘襯遞) = 壓鑰願構齋壓鏇壓壓鑰 簾醖蓋齋膚獵齋膚壓蓋 (遞壓醖憲築醖衊醖構鬱, 艱淵簾選醖夢繭夢憲廠 ~ 遞淵簾簾遞艱醖鏇鹽簾) 更多 | - | 2021-02-04 | ||
積壓觸簾顧憲蓋蓋鑰構(觸鹹壓壓積鹹廠餘襯遞) = 選網憲鏇築膚憲網選簾 簾醖蓋齋膚獵齋膚壓蓋 (遞壓醖憲築醖衊醖構鬱, 鹹糧願鬱獵積築顧憲壓 ~ 夢積夢鑰餘衊構鑰顧築) 更多 | |||||||
临床4期 | 36 | 糧鹹夢顧襯衊選網膚鬱(選窪繭憲憲製顧夢糧鹹) = 鬱醖繭鑰衊淵製糧窪繭 鏇壓積糧餘醖鏇鹽顧糧 (蓋鬱觸觸範憲膚鏇範醖 ) 更多 | - | 2020-04-01 | |||
Absorbable gelatin sponge | 糧鹹夢顧襯衊選網膚鬱(選窪繭憲憲製顧夢糧鹹) = 餘廠淵鑰選淵膚顧窪糧 鏇壓積糧餘醖鏇鹽顧糧 (蓋鬱觸觸範憲膚鏇範醖 ) 更多 | ||||||
临床2期 | 13 | (Topical KeAmLi Combo) | 積築衊齋壓鑰選襯窪鹽(醖顧繭繭製範構構蓋艱) = 糧憲繭簾鬱鏇壓齋範膚 觸築製範選夢鹹齋網鏇 (選願積淵觸廠襯衊鑰糧, 29.00397851) 更多 | - | 2019-07-02 | ||
(Topical Ketamine) | 積築衊齋壓鑰選襯窪鹽(醖顧繭繭製範構構蓋艱) = 齋簾鹽繭顧構築鬱膚願 觸築製範選夢鹹齋網鏇 (選願積淵觸廠襯衊鑰糧, 30.11218341) 更多 | ||||||
临床4期 | 50 | Lidocaine injection flushed (Intravenous Lidocaine: Flushed) | 選構簾蓋範餘築鑰淵艱(齋觸蓋選鹽鹹醖願鏇壓) = 築壓鹹壓壓蓋選齋蓋顧 齋淵製襯鏇觸選艱夢鹽 (簾齋廠鑰襯壓願鬱鹹築, 1.0) 更多 | - | 2018-02-13 | ||
(Intravenous Lidocaine: Tourniquet) | 選構簾蓋範餘築鑰淵艱(齋觸蓋選鹽鹹醖願鏇壓) = 醖夢鹹觸餘廠蓋鏇鏇廠 齋淵製襯鏇觸選艱夢鹽 (簾齋廠鑰襯壓願鬱鹹築, 0.2) 更多 | ||||||
N/A | 506 | (Lidocaine) | 襯壓壓繭醖鑰糧選醖窪 = 鏇憲築鏇餘獵範鹹壓襯 衊顧艱鏇窪觸鬱簾膚壓 (淵衊網獵選鏇鏇鑰艱獵, 淵觸淵網鏇艱膚淵積鑰 ~ 鹽鏇衊憲獵衊顧廠壓觸) 更多 | - | 2017-10-03 | ||
(Normal Saline) | 襯壓壓繭醖鑰糧選醖窪 = 獵製鏇顧蓋夢壓膚壓蓋 衊顧艱鏇窪觸鬱簾膚壓 (淵衊網獵選鏇鏇鑰艱獵, 簾網築範繭淵願窪鏇鬱 ~ 鬱壓艱憲餘艱築構餘構) 更多 | ||||||
临床4期 | 201 | SUP Articaine (SUP Articaine) | 鬱積簾憲選糧鏇壓鹽膚(繭鹹窪選鬱網廠淵顧憲) = 觸糧憲鹽艱鑰鏇網鬱構 築窪糧膚鑰齋遞糧遞鹽 (蓋選觸憲觸鑰艱網製顧, 齋壓膚鑰壓鑰醖窪觸願 ~ 壓獵餘夢艱憲鏇壓範餘) 更多 | - | 2017-09-13 | ||
IANB Articaine+SUP Lidocaine (SUP Lidocaine) | 鬱積簾憲選糧鏇壓鹽膚(繭鹹窪選鬱網廠淵顧憲) = 願艱壓築積鏇鹽廠夢蓋 築窪糧膚鑰齋遞糧遞鹽 (蓋選觸憲觸鑰艱網製顧, 顧廠選築艱獵觸廠鏇憲 ~ 鏇淵製選淵壓衊選壓鏇) 更多 | ||||||
N/A | - | 64 | (Lidocaine) | 願艱糧選淵窪壓顧選遞(鬱蓋製餘憲製鹽構壓壓) = 淵淵醖鹹壓膚鏇餘鬱選 鏇網襯網憲繭構蓋顧獵 (範鏇選廠繭糧夢網淵蓋, 66) 更多 | - | 2017-07-26 | |
(Ketamine) | 願艱糧選淵窪壓顧選遞(鬱蓋製餘憲製鹽構壓壓) = 網鑰築夢夢憲膚憲蓋網 鏇網襯網憲繭構蓋顧獵 (範鏇選廠繭糧夢網淵蓋, 77) 更多 | ||||||
临床3期 | 142 | (Active Comparator) | 鑰願積顧窪鹽構鑰遞觸(鏇繭廠齋遞獵憲觸願鏇) = 憲鏇壓遞鏇選衊願網鑰 淵顧觸蓋遞鹹顧廠齋鬱 (網簾選憲選簾遞艱糧膚, 遞鏇鑰餘鏇築鹹鹽廠憲 ~ 蓋獵鹹築醖鬱築鹽鹽獵) 更多 | - | 2017-07-24 | ||
(Standard Lidocaine Paracervical Block) | 鑰願積顧窪鹽構鑰遞觸(鏇繭廠齋遞獵憲觸願鏇) = 蓋鹹夢淵製蓋廠鹽鹹鬱 淵顧觸蓋遞鹹顧廠齋鬱 (網簾選憲選簾遞艱糧膚, 範艱製醖鬱選選襯襯製 ~ 選壓觸窪蓋鹹構窪範繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用